Abstract: Hypertrophic cardiomyopathy (HCM) is a disease characterized by primary hypertrophy of the left (and sometimes right) ventricle. The clinical manifestations of the disease are dyspnea, angina, and a continuum encompassing lightheadedness, presyncope, syncope, and sudden death. Although HCM is often caused by an identifiable mutation in a gene coding for a sarcomeric protein and inherited in an autosomal-dominant pattern, many patients do not have any relatives in whom the disease is manifest. The prevalence of HCM is estimated to be 0.2%, with nearly 600,000 Americans affected. This limited exposure of clinicians to HCM understandably accounts for the uncertainty that prevails regarding this disease and its management.
H ypertrophic cardiomyopathy (HCM) is defined clinically by establishing left ventricular hypertrophy (LVH) which is typically asymmetric in distribution, and showing virtually any diffuse or segmental pattern of LV wall thickening in the absence of cardiac or systemic disease such as hypertension or aortic stenosis.
1,2 LV wall thickening is associated with a nondilated and hyperdynamic chamber often with systolic cavity obliteration capable of producing the hypertrophy (independent of whether or not LV outflow obstruction is present). 3, 4 Several anatomic variants of HCM exist. Of these, hypertrophic obstructive cardiomyopathy (HOCM) is the variant that has been the subject of the most intense investigation. Epidemiological investigations with diverse study designs have shown similar estimates for prevalence of phenotypically expressed HCM in the adult general population at about 0.2% (1:500). 5 Therefore, HCM is considered the most common genetic cardiovascular disease, with reports from many countries. Nevertheless, a substantial proportion of individuals harboring a mutant gene for HCM are probably undetected clinically. HCM is uncommon in routine cardiologic practice, affecting no more than 1% of outpatients. 6 HOCM was previously termed idiopathic hypertrophic subaortic stenosis and is characterized by 4 closely related patho-anatomic features (Fig. 1) . 7 Obstruction to LV outflow is caused by bulging of the thickened septum into the left ventricular outflow tract (LVOT) during systole, with apposition of the anterior and occasionally posterior leaflet of the mitral valve, which demonstrates systolic anterior motion. Mitral regurgitation usually is present, although the degree varies greatly among patients with HCM. LVOT gradients may be present at rest or only during valsalva maneuver or exercise (provocable obstruction).
A recent report suggests that if patients with provocable gradients are included, most patients with HCM have the obstructive form of the disease. 8 However, most of the studies have shown that HCM is predominantly a nonobstructive disease and nearly 75% of patients do not have a sizable resting OT gradient.
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EPIDEMIOLOGY
HCM caused by sarcomere mutations may account for up to 60% of unexplained LVH, making HCM the most common genetic cardiovascular disorder. [12] [13] [14] HCM is referenced as the most common cause of sudden cardiac death (SCD) among athletes, yet recent studies present conflicting data. 15, 16 One study of Italian athletes found that only 2% of sudden death among athletes were due to HCM compared with 7.3% in the nonathlete group. 17 A similar study of American Army recruits involved in intensive basic training found that among 64 recruits that experienced SCD, only 13% of sudden death were due to HCM and 61% were due to anomalous coronary artery insertion. 18 In contrast, a study looking at SCD among American football and basketball players found 36% of all deaths were due to HCM. 19 The incidence of SCD is most frequent in adolescents and young adults less than 35 years of age. This risk also extends through midlife and beyond. Therefore, we should understand that achieving any particular age does not confer immunity to sudden HCM-related catastrophe. 20 A recent study investigating the relationship between gender and HCM found that women differ in physical complications and clinical severity. Women suffer stroke more often, progress to heart failure with New York Heart Association class III to IV 50% more, are older at presentation, and have a greater degree of LVOT obstruction.
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ETIOLOGY
A minor but still significant number of patients have a family history of HCM-up to one-third in some series. HCM is inherited as a Mendelian autosomal dominant trait and caused by mutations in any 1 of 11 genes, each encoding proteins of the cardiac sarcomere (components of thick or thin filaments with contractile, structural, or regulatory functions). 22, 23 The physical similarity of these proteins makes it possible to regard the diverse HCM spectrum as a single disease entity and primary sarcomere disorder. Three of the HCM-causing mutant genes predominate, namely, ␤-myosin heavy chain (the first identified), cardiac troponin T, and myosin-binding protein C. The mechanisms by which disease-causing mutations cause LVH and the HCM disease state are unresolved, although several hypotheses have been suggested. 24 HCM is caused by dominant mutations in genes that encode constituents of the sarcomere. More than 400 individual mutations have been identified in 11 sarcomere genes summarized in Table 1 (and at http://cardiogenomics.med. harvard.edu/mutation-db.tcl), 13, [25] [26] [27] including cardiac ␤-and ␣-myosin heavy chains; cardiac troponins T, I, and C; cardiac myosin binding protein C; ␣-tropomyosin; actin; the essential and regulatory myosin light chains; and titin. A few families have demonstrated a high incidence of premature death or end-stage heart failure, defining their mutations as potentially "malignant." Others are associated with distinctive HCM morphology; eg, familial inheritance of apical pattern hypertrophy has been associated with mutations in cardiac actin. 28 The titin gene locus on chromosome 2q31 has long been recognized as a strong candidate for dilated CM but there are 2 specific mutations in titin that are related to HCM. 29 Currently it has been shown that all segments in human titin (Z-disk, I-band, A-band, M-band) are affected by mutations causing various forms of hereditary myopathies like HCM. The huge size of this molecule and the prevalence of the mutations already found suggest that titin mutations may be a more common cause of human myopathies. 29 An interesting yet perplexing story recently has arisen from studying a newly characterized Z-line titin-binding protein. This giant molecule was named obscurin because its complexity, large size (700 -800 kDa), and low abundance hindered its characterization. 30 This 800-kDa-protein obscurin is expressed in different cardiac isoforms, the composition of which can be altered in human CMs. 31 A HCM-associated titin/connectin mutation (Arg740Leu) was found to increase the binding to actinin, whereas other dilated CM-associated titin/connectin mutations (Ala743Val and Val54Met) decreased the binding to actinin and Tcap/telethonin, respectively. Several other mutations in N2-B region of titin/connectin are also found in HCM. 32 Because the N2-B region expresses only in the heart, it was speculated that functional alterations due to the mutations cause CMs. 
CLINICAL PRESENTATION AND PATHOPHYSIOLOGY
Age of onset of LVH ranges from early childhood to late adulthood and depends, in part, on the underlying genetic cause. 33, 34 The 3 cardinal manifestations of HCM histopathology (cardiac hypertrophy, myocyte fibrosis, and disarray) reflect independent pathologic processes within myocytes carrying a sarcomere gene mutation (Fig. 2) . 27, 35 Although small amounts of myocyte disarray and fibrosis may be seen in other forms of cardiac disease, the higher degree present in HCM is distinctive. In their absence, the diagnosis of HCM should be questioned. 35, 36 The spectrum of HCM is broad. Diagnosis of some individuals occurs incidentally during the investigation of asymptomatic murmurs or with family screening (Table 2) 27 ; others present with dyspnea, chest pain, or exercise intolerance. Chest pain in the absence of coronary atherosclerosis, possibly due to microvascular dysfunction and ischemia, is also present in a minority of patients. 4, [37] [38] [39] [40] Outflow obstruction is associated with an increased risk of heart failure and death. 39, 41 Clinical progression can be indolent or more rapidly result in refractory symptoms and heart failure.
With gene-based diagnosis and newer imaging techniques, there is increased recognition that LVH is neither the most specific nor sensitive manifestation of HCM. Studies of preclinical individuals with sarcomere gene mutations demonstrate that diastolic abnormalities, detected by Doppler tissue imaging, develop in advance of LVH. 42, 43 The clinical course of HCM is typically variable, and patients may remain stable over long periods with up to 25% living more than 75 years. 4, 44 However, many patients are affected by adverse clinical events, mostly related to sudden, unexpected death, embolic stroke, and heart failure. 4, 44 In general, adverse clinical course proceeds along one of several of the following pathways. 40 1. Premature sudden and unexpected death. 2. Symptoms due to exertional dyspnea, chest pain, and syncope, near-syncope or presyncope. 3. Congestive heart failure with LV remodeling and systolic dysfunction. 4. Complications due to arrhythmias, especially atrial fibrillation.
DIFFERENTIAL DIAGNOSIS OF UNEXPLAINED LVH
Genetic studies of familial and sporadic unexplained LVH accompanied by conduction abnormalities (progressive atrioventricular block, atrial fibrillation, ventricular pre-excitation/Wolff-Parkinson-White syndrome) have identified metabolic CMs. These genetic forms of hypertrophy reflect mutations in the ␥2 regulatory subunit (PRKAG2) of adenosine monophosphate-activated protein kinase, an enzyme involved with glucose metabolism, or in the X-linked lysosome-associated membrane protein (LAMP2) gene. 12, [45] [46] [47] These clinical entities are distinct from HCM caused by sarcomere protein mutations, despite the shared feature of LVH. The histopathology of PRKAG2 and LAMP2 mutations shows prominent nonmembrane-bound vacuoles containing glycogen and amylopectin rather than the myocardial disarray or interstitial fibrosis characteristic of HCM (Fig. 2) . Although incompletely defined, the molecular signaling pathways triggered by PRKAG2 and LAMP2 mutations are almost certainly different from those produced by sarcomere gene mutations.
DIAGNOSIS
The 2D echocardiogram is used in establishing LVH which is typically asymmetric in distribution, and showing virtually any diffuse or segmental pattern of LV wall thickening. LV wall thickening is associated with a nondilated and hyperdynamic chamber often with systolic cavity obliteration. [3] [4] [5] The clinical diagnostic criteria for HCM is a maximal LV wall thickness Ն15 mm, but genotype-phenotype correlations have shown that even a normal wall thickness is compatible with the presence of a HCM mutant gene. 48, 49 Physiological changes of an athelete's heart should be distinguished from mildly increased LV wall thickness of 13-14 mm due to HCM. 5,50 -52 Magnetic resonance imaging provides high-resolution tomographic images of the entire LV. This can be used as a complementary diagnostic modality, particularly in the presence of suboptimal echocardiographic studies or when segmental hypertrophy is confined to unusual locations within the LV wall. 50 In resting (basal) conditions, most patients with HCM do not demonstrate an outflow obstruction, although many may develop dynamic subaortic gradients of varying magnitude with provocative maneuvers or agents. 53, 54 Clinical features of HCM, namely LVH on echocardiogram, abnormal ECG pattern, or disease-related symptoms are not present at all times during life, even in individuals with genetic defect. 55, 56 In young patients, ECG abnormalities or evidence of diastolic dysfunction assessed by Doppler tissue imaging may even precede the appearance of the phenotype on echocardiogram. 55, 56 In fact, clinical and molecular genetic studies have demonstrated that there is no minimum LV wall thickness required for a diagnosis with the presence of an HCM causing mutant gene. 23 Laboratory DNA analysis for mutant genes is the most definitive method for establishing the diagnosis of HCM, but there are various obstacles in applying genetic research in clinical practice.
MANAGEMENT
Because HCM is a relatively rare condition, and events are uncommon, none of the pharmacologic or nonpharmacologic treatment strategies are based (and probably will never 
Pharmacologic Management
Because there is no data to indicate that pharmacological therapy may change the course of HCM, treatment is generally not required in low-risk asymptomatic patients. Dyspnea on exertion represents the most common symptom. Heart failure is caused in large measure by diastolic dysfunction with impaired LV filling, in the presence of preserved systolic function. 4, 16, 38, 40 Pharmacological treatment of heart failure has traditionally been based on the administration of ␤ blockers (Fig. 3) . 11 By reducing the heart rate, these drugs prolong diastole and improve ventricular filling. ␤ Blockers are used preferably for symptomatic patients with outflow gradients presenting with exertion. Verapamil may be used in patients without severe outflow obstruction and is the drug of first choice in patients whose main symptom is chest pain. 4, 16, 38, 40 In patients with heart failure despite treatment with ␤ blockers or verapamil, the addition of diuretics in low doses is usually effective in alleviating symptoms. 4, 16, 38, 40 Angiotensin converting enzyme (ACE) inhibitors must be used with caution, because by reducing the afterload they may either favor the development of or increase outflow obstruction.
About 5% of patients evolve toward the end stage phase of HCM, characterized by systolic dysfunction and usually associated with thinning of the LV wall (due to extensive fibrosis) and cavity dilatation. [57] [58] [59] Such patients are candidates to standard treatment of heart failure secondary to systolic dysfunction, including ACE inhibitors, diuretics, ␤ blockers, and digitalis. 4, 38, 40, 59 Ultimately, many of these patients become candidates for heart transplantation. 59 Because of their high risk for SCD, a cardioverter defibrillator should be considered as a bridge to transplantation. Paroxysmal or chronic atrial fibrillation develops in about 20% of adult patients with HCM and is associated with an increased risk of death due to heart failure. 59 Oral anticoagulant therapy is indicated in patients with either paroxysmal or chronic atrial fibrillation, because even a single episode of atrial fibrillation is associated with a substantial increase in the risk of systemic embolization. 4, 38, 40, 59 Infective endocarditis is very uncommon and occurs almost exclusively in patients with outflow obstruction at rest. The vegetations are usually located on the thickened anterior mitral leaflet, less commonly on the aortic valve. The American Heart Association's recommendations for prevention of infective endocarditis should be applied only to patients with obstruction at rest.
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Drugs to be Avoided 40 Nifedipine may be deleterious, particularly for patients with outflow obstruction because of its potent vasodilating property. Because of their proarrhythmic properties, combination therapy with disopyramide and amiodarone, disopyramide and sotalol, quinidine and verapamil, or quinidine and procainamide should be avoided. In patients with resting or provocable outflow obstruction, administration of nitroglycerine, ACE inhibitors, or digitalis are generally contraindicated or discouraged. High-dose amiodarone, especially Ͼ400 mg per day, should be used with caution in patients with severe heart failure. Many patients with HCM have diastolic dysfunction and require relatively high filling pressures to achieve adequate ventricular filling, therefore it is advisable to administer diuretics cautiously. In patients with erectile dysfunction, phosphodiesterase inhibitors can cause a mild afterload reducing effect, which may be deleterious in patients with resting or provocable obstruction.
Nonpharmacologic Management
The original mechanical management of patients with HOCM and refractory symptoms consisted of septal myotomy, or simple incision of septal muscle, first performed in 1958. 58, 60 Myotomy was soon replaced by septal myectomy, or removal of septal muscle. 61, 62 Dr. W.P. Cleland at Hammersmith Hospital (London) was the first surgeon to perform a myectomy, 60 but the operation was soon abandoned in the United Kingdom for decades. Thereafter, Drs. Andrew Morrow at the National Institutes of Health, John Kirklin at the Mayo Clinic, and Wilfred Bigelow and William Williams at Toronto General pioneered surgical intervention (first myotomy and then myectomy), permitting surgical myectomy to emerge as the primary treatment option for severely symptomatic drug-refractory patients with outflow obstruction in many centers throughout the world. 16, 40, 47, [63] [64] [65] [66] [67] [68] In the most recent long-term postoperative analysis, almost 85% of patients became asymptomatic or only mildly symptomatic (New York Heart Association class I or II) an average of 8 years (and up to 25 years) after myectomy. 68 No evidence exists that myectomy itself increases arrhythmogenicity or predisposes to systolic dysfunction and the end stage of the disease. 69 Furthermore, the preponderance of evidence from observational, comparative studies with alcohol septal ablation shows that myectomy affords more consistent and complete hemodynamic and symptomatic benefit and is associated with fewer procedural complications and reinterventions. 70 -75 In addition to heart failure reversal, myectomy also promotes long-term survival. Operated patients experience enhanced longevity indistinguishable from that expected in the general population and superior to that of nonoperated patients with obstruction 66, 76 (Fig. 4) . After myectomy, survival free from all-cause mortality is 98%, 96%, and 83% at 1, 5, and 10 years, and survival free from HCM-related mortality (heart failure and sudden death) is 99%, 98%, and 95%, respectively. 66 Therefore, surgical septal myectomy favorably alters the natural course of HCM, providing a reasonable expectation for normal or nearly normal life expectancy.
Transcatheter ablation of the septum with ethanol was first performed at the Royal Brompton Hospital in London in 1994. 76, 77 In 1995, Dr. Ulrich Sigwart applied percutaneous methodology to HCM in which 2-4 cm 33 of 96% ethanol is introduced into a septal perforator branch of the left anterior descending coronary artery (often guided by myocardial contrast echocardiography) to intentionally produce an infarction in the ventricular septum. 76 After a transient drop in gradient as a result of stunning, ultimate resolution of obstruction requires several months of septal remodeling, leading to outflow tract widening and reduced mitral valve systolic anterior motion. 73, 74 Ablation reduces LVOT obstruction, although on average somewhat less than myectomy (residual rest gradient, 20 -25 vs. 0 -10 mm Hg for surgery). 70 -73 Because the proximal septal branches of the left anterior descending coronary artery supply the conduction system as well as the basal septum, atrioventricular block is a common complication of septal ablation. For this reason, a temporary pacemaker is placed before the procedure.
There have been no prospective randomized trials comparing septal ablation with septal myectomy. Investigators have compared the results of septal ablation with those of septal myectomy in several nonrandomized studies. 43,70 -72 In none of these retrospective studies have patients been adequately matched for age, gender, and other clinical predictors of outcome in HOCM. Thus, although some have expressed strong, well-reasoned opinions in support of either septal ablation 78 or septal myectomy 47 as the procedure of choice, existing data are inconclusive, so the management decision in many cases depends critically on patient choice.
Dual-chamber pacing with a short atrioventricular delay was suggested as early as 1968 as an innovative approach for the management of HCM. 79 Although marked beneficial effects of pacing were reported in uncontrolled series, these findings have not been reproduced in randomized controlled trials, although a suggestion exists that a small subset of patients benefits from pacing. 80 Ongoing research in animal models of HCM has illuminated disease mechanisms. Promising results have been seen with therapeutic strategies to manipulate intracellular calcium handling in prehypertrophic mice, 81 as well as with treatment targeted against myocardial fibrosis (with angiotensin II receptor blockers, aldosterone antagonists, and HMG-CoA reductase inhibitors) in animals with overt HCM. 36, 82, 83 Translation into human clinical protocols may be beneficial and presents an exciting new treatment paradigm with a goal of altering phenotype rather than merely palliating symptoms. 
RISK STRATIFICATION
SCD is the most common modality of death in HCM and occurs more commonly in young asymptomatic or only mildly symptomatic patients. 4, 38, 40 Indeed, HCM is the most common cause of SCD in athletes. 4, 38, 40 Patients who have survived a cardiac arrest, or experienced one or more episodes of sustained ventricular tachycardia, are considered at high risk and definite candidates to a cardioverter defibrillator for secondary prevention of SCD. 4,38,40,84 -86 These patients, however, represent only a small percentage of the patients with HCM. Greater uncertainty persists with regard to the selection of patients for primary prophylactic implantation of a cardioverter defibrillator. As a general strategy, multiple risk factors are considered to convey a greater likelihood of SCD. 4, 38, 40 However, a single and strong risk factor may also be an indicator of high risk in selected patients. 40 In the United States and most European countries, a family history with 2 or more premature SCDs is considered a justification for implantation of a cardioverter defibrillator. 86, 87 Extreme thickness of the LV wall (Ն30 mm) is a strong predictor of SCD in young patients with HCM and is associated with an estimated long-term risk of SCD of about 40% at 20 years. 40, 88 Therefore, serious consideration should be given to implantation of a cardioverter defibrillator in young patients with extreme hypertrophy, independently of the presence of other risk factors. 40, 88 In young patients, unexplained (not neurally mediated) syncope at rest or during effort is generally considered a marker of increased risk and a possible indication to a cardioverter defibrillator. 4, 38, 40 In young patients (Յ30 years), brief runs of nonsustained ventricular tachycardia (3 or more beats) on Holter monitoring are associated with a significant increase in the risk for SCD. 89 In such patients, multiple or prolonged runs of nonsustained ventricular tachycardia may be of particular concern and raise the issue of implantation of a cardioverter defibrillator, even in the absence of other risk factors. 40 Hypotensive blood pressure response during upright exercise seems to convey an increased risk for SCD and may be included in the overall risk profile, particularly in patients younger than 50.
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CONCLUSIONS
Integration of genotype information with comprehensive clinical evaluation and risk assessment is appropriate and necessary for optimal patient management. For patients at high risk of SCD, implantation of a cardioverter-defibrillator is considered. 86 In most patients, symptoms can be adequately controlled with the medications used alone or in combination. In patients with HOCM and symptoms refractory to optimal medical therapy, mechanical measures aimed at relief of the LVOT obstruction are considered.
